Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group (Q74036129)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 January 1998

Language	Label	Description	Also known as
English	Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group	scientific article published on 01 January 1998

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9428213%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9428213%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

author name string

J R Green

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9428213%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

A J Lobo

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9428213%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

C D Holdsworth

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9428213%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

R J Leicester

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9428213%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

J A Gibson

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9428213%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

G D Kerr

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9428213%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

H J Hodgson

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9428213%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

K J Parkins

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9428213%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

M D Taylor

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9428213%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

language of work or name

0 references

publication date

1 January 1998

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9428213%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9428213%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

114

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9428213%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9428213%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

15-22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9428213%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

Some aspects of the epidemiology of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970627-4

7 January 2021

Drug management of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970627-4

7 January 2021

Drug therapy of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970627-4

7 January 2021

Sulphasalazine and salicylazosulphadimidine in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970627-4

7 January 2021

Sulfasalazine. Adverse effects and desensitization

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970627-4

7 January 2021

Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970627-4

7 January 2021

An experiment to determine the active therapeutic moiety of sulphasalazine

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970627-4

7 January 2021

An oral preparation to release drugs in the human colon

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970627-4

7 January 2021

Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970627-4

7 January 2021

Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970627-4

7 January 2021

Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970627-4

7 January 2021

Treatment of ulcerative colitis with oral 5-aminosalicyclic acid in patients unable to take sulphasalazine

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970627-4

7 January 2021

Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970627-4

7 January 2021

Medical therapy of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970627-4

7 January 2021

Reversal with balsalazide of infertility caused by sulphsalazine

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970627-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970627-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0016-5085(98)70627-4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9428213%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9428213%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q74036129&oldid=1743693143"